Merck’s ambitious endeavor to develop a Hepatitis C drug and outdo Gilead has fallen short. Merck’s attempt to reduce treatment duration by combining two of its drugs with Gilead’s drug Sovaldi has failed to achieve the desired result. Interim data released by Merck show that this failure happened due to high rate of relapses.
Several pharma companies are trying to develop a therapy or treatment for Hepatitis C that would be short as well as effective in treating the disease. A pill known as Harvoni requires eight weeks to treat some patients. Harvoni is a combination of Sovaldi and another Gilead drug.